Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,030.00
-190.00 (-2.06%)
Oct 10, 2025, 3:30 PM KST
-2.06%
Market Cap214.43B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out23.26M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume65,345
Average Volume111,580
Open9,220.00
Previous Close9,220.00
Day's Range8,970.00 - 9,230.00
52-Week Range6,970.00 - 14,950.00
Beta3.08
RSI46.78
Earnings DateNov 11, 2025

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements

News

There is no news available yet.